MAIA Biotechnology, Inc. is a cutting-edge, early stage biotech company, dedicated to developing targeted cancer therapies with novel mechanisms of action that are intended to meaningfully improve and extend the lives of patients with cancer. A privately-held company based in Chicago and Houston, MAIA is led by a passionate, principled and dynamic Management Team with significant drug development experience, committed to advancing promising agents into trials in humans in the next 3-5 years.
THIO (6-thio-dG) targets tumor cell DNA and causes damage to DNA ends (telomeres), resulting in the selective death of tumor cells. This approach targets an almost universal driver of tumor growth and is supported by extensive preclinical work showing very significant antitumor activity across a broad range of tumors refractory to immuno-oncology agents, targeted therapies, and chemotherapy. Currently, patients failing these treatments have a poor prognosis and few alternative treatment options. THIO utilizes a novel mechanism of action to target advanced solid tumors, and is currently in preclinical development stage.
MJC13 targets the regulation of androgen receptor (AR) by binding to a recently identified regulatory surface on AR (BF3). MJC13 effectively blocks β-catenin interaction with the AR ligand binding domain and the synergistic up-regulation of AR by FKBP52 and β-catenin. MJC13 was shown to effectively block AR signaling and AR-dependent cancer cell proliferation in a variety of human prostate cancer cell lines, and preclinical studies demonstrate impressive effects on tumor growth in a prostate cancer xenograft model.
GMC1 is a FKBP52 co-chaperone-inhibitor for prostate cancer. GMC1 engages a new pharmacologic target, FKBP52 (FK506 binding protein), to inhibit Androgen Receptor (AR) signaling. FKBP52 is a cofactor required for stabilization and activity of AR. GMC1 binding to FKBP52 preventing AR-regulated gene expression and tumor cell growth. This “indirect” inhibition of AR-signaling is not affected by resistance mechanisms common to standard-of-care drugs in prostate cancer. GMC1 utilizes a novel mechanism of action to target prostate cancer, and is currently in the lead selection stage.
MBT-826 is a novel synthesized derivative of the natural product Indigo. Those compounds are strong inhibitors of cyclin-dependent kinases (CDKs), glycogen synthase kinase-3β, c-Src kinase and signal transducer and activator of transcription 3 (STAT3), and an inhibitor of Survivin leading to apoptosis in cancer cells. MBT-826 has potential for multiple tumor types and is currently in drug discovery stage.